Medicine and HealthInternational Journal of Molecular Sciences
The Long Run towards Personalized Therapy in Non-Small-Cell Lung Cancer: Current State and Future Directions
C. Genova
Explore the latest advancements and ongoing challenges in personalized therapy for non-small-cell lung cancer (NSCLC) as discussed by Carlo Genova. This insightful editorial delves into the complexity of NSCLC treatment, including the rise of targeted therapies and the fascinating role of artificial intelligence in enhancing personalized medicine.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Prolonged response to first-generation tyrosine kinase inhibitor in a metastatic non-small cell lung cancer harbouring complex G719X and S768I mutations: A case report from Vietnam and literature review
K. H. Do, D. T. Le, et al.
Medicine and Health
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
B. Besse, E. Pons-tostivint, et al.
Medicine and Health
Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer
Y. Zeng, C. Hu, et al.
Medicine and Health
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
S. Peters, S. M. Gadgeel, et al.
